Literature DB >> 25359597

[A practically orientated clinical HIV update for ENT physicians].

M Unnewehr1, C Sieling, B Schaaf.   

Abstract

Basic knowledge concerning the human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) is useful for ENT physicians. Although HIV patients are usually stably asymptomatic nowadays due to modern therapy, HIV often manifests in ENT symptoms, such as neck lumps, sore throat, difficulty swallowing and dysgeusia. After infection, an initial increase in viral load can cause, among other symptoms, oral ulcers and pharyngitis. Once the immune system is compromised by the attack on CD4 lymphocyte cells, HIV-related diseases can occur: oral mycoses (particularly candidosis) and viral infections (including warts), aphthous ulcers, gingivitis, salivary gland diseases and malignancies (e. g. intraoral Kaposi's sarcoma). Neck lymphadenopathy is frequent. Markers of disease severity are the clinical symptoms, viral load and CD4 helper cell count. HIV treatment (antiretroviral therapy, ART) is a combination of at least three antiviral drugs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25359597     DOI: 10.1007/s00106-014-2937-y

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  3 in total

1.  [Viral sialadenitis].

Authors:  J Ussmüller
Journal:  HNO       Date:  2010-03       Impact factor: 1.284

2.  The Oral HIV/AIDS Research Alliance: updated case definitions of oral disease endpoints.

Authors:  C H Shiboski; L L Patton; J Y Webster-Cyriaque; D Greenspan; R S Traboulsi; M Ghannoum; R Jurevic; J A Phelan; D Reznik; J S Greenspan
Journal:  J Oral Pathol Med       Date:  2009-07       Impact factor: 4.253

3.  Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066).

Authors:  J Thoden; A Potthoff; J R Bogner; N H Brockmeyer; S Esser; K Grabmeier-Pfistershammer; B Haas; K Hahn; G Härter; M Hartmann; C Herzmann; J Hutterer; A R Jordan; C Lange; S Mauss; D Meyer-Olson; F Mosthaf; M Oette; S Reuter; A Rieger; T Rosenkranz; M Ruhnke; B Schaaf; S Schwarze; H J Stellbrink; H Stocker; A Stoehr; M Stoll; C Träder; M Vogel; D Wagner; C Wyen; C Hoffmann
Journal:  Infection       Date:  2013-09-14       Impact factor: 3.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.